Lipid nanoparticles (LNPs) play an important role in mRNA vaccines against COVID-19. In
addition, many preclinical and clinical studies, including the siRNA-LNP product, Onpattro® …

RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

Liposomes are considered among the most versatile and advanced nanoparticle delivery
systems used to target drugs to specific cells and tissues. Structurally, liposomes are sphere …

The increasing number of approved nucleic acid therapeutics demonstrates the potential to
treat diseases by targeting their genetic blueprints in vivo. Conventional treatments …

Lipid nanoparticles (LNPs) are a clinically mature technology for the delivery of genetic
medicines but have limited therapeutic applications due to liver accumulation. Recently, our …

RNA-based therapeutics have shown great promise in treating a broad spectrum of
diseases through various mechanisms including knockdown of pathological genes …

Hereditary genetic diseases, cancer, and infectious diseases are affecting global health and
become major health issues, but the treatment development remains challenging. Gene …

COVID-19 vaccines have been developed with unprecedented speed which would not have
been possible without decades of fundamental research on delivery nanotechnology. Lipid …

Abstract mRNA-Lipid nanoparticles (LNPs) are at the forefront of global medical research.
With the development of mRNA-LNP vaccines to combat the COVID-19 pandemic, the …

Nanocarriers have therapeutic potential to facilitate drug delivery, including biological
agents, small-molecule drugs, and nucleic acids. However, their efficiency is limited by …